Suppr超能文献

[男性乳腺癌的临床研究进展]

[Clinical research advancement on male breast cancer].

作者信息

Xue Yan, Guo Xiao-Tong, Liu Wen-Chao

机构信息

Department of Oncology, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi, 710032, P. R. China.

出版信息

Ai Zheng. 2007 Oct;26(10):1148-52.

Abstract

Male breast cancer is a rare disease and the incidence has increased over the past 25 years. Current knowledge regarding its biology, natural history, and treatment strategies is mainly based on the research findings on female breast cancer. Genetic risk factors include BRCA2 mutations. Occupational risk factors include high temperature environments and exhaust fumes. Hormonal imbalances, such as gonadal dysfunction, obesity, and radiation exposure also contribute to the occurrence of male breast cancer. It may be indolent or progress slowly, or invade rapidly. Most cases are ductal tumors and 10% of the cases are ductal carcinoma in situ. The surgical operation is usually mastectomy with axillary clearance or sentinel node biopsy. Indications for radiotherapy, as well as the steps and methods, are similar to that for female breast cancer. Because 90% of the patients are estrogen receptor-positive, tamoxifen is a standard adjuvant therapy, but some individuals could also benefit from chemotherapy. In this article, the latest information on the epidemiology, biology, and treatment of male breast cancer is reviewed.

摘要

男性乳腺癌是一种罕见疾病,在过去25年中其发病率有所上升。目前关于其生物学、自然史和治疗策略的知识主要基于对女性乳腺癌的研究结果。遗传风险因素包括BRCA2突变。职业风险因素包括高温环境和废气。激素失衡,如性腺功能障碍、肥胖和辐射暴露也会导致男性乳腺癌的发生。它可能发展缓慢或进展缓慢,也可能迅速侵袭。大多数病例为导管肿瘤,10%的病例为导管原位癌。手术通常是乳房切除术加腋窝清扫或前哨淋巴结活检。放疗的适应证以及步骤和方法与女性乳腺癌相似。由于90%的患者雌激素受体呈阳性,他莫昔芬是标准的辅助治疗药物,但一些患者也可能从化疗中获益。本文综述了男性乳腺癌流行病学、生物学和治疗方面的最新信息。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验